Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
109 participants
INTERVENTIONAL
2017-09-01
2019-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main aim of this study is to measure the amount of variation in blood LDL-cholesterol in healthy male volunteers in response to the replacement of SFA with unsaturated fats, and to select LDL-C responders from non-responders for a subsequent metabolic study ('RISSC-2'). Estimate of statistical power and sample size for 'RISSCI-1': A decrease of 0.16 mmol/L (SD 0.54) in our primary outcome of fasting plasma LDL-C between the high- and low-SFA diets, as observed in a previous randomly controlled trial, will require a sample size of 92 participants, at 80% power and 5% significance level. An estimated attrition rate of 15% will increase this sample size to 106 participants. To recruit this sample of participants, we anticipate having to screen 150 volunteers (75 at each site).
Specific objectives:
1. Undertake a dietary intervention study to examine the effects of two, 4 week diets that differ in their composition of fatty acids. The first diet ('Diet 1') will contain \~18% of its total energy as saturated fatty acids (SFA), while the second diet ('Diet 2') will contain \~10% of its total energy as SFA. Blood, urine and stool samples taken at the beginning (week 0) and end of Diet 1 (week 4), and end of Diet 2 (week 8), will be analysed to measure blood LDL-cholesterol and other relevant blood, urine and faecal metabolites. The white blood cell buffy coat will also be isolated from the blood samples collected at the baseline visit to enable genotyping of relevant genes involved in the absorption and metabolism of dietary fat.
2. To examine the data for evidence of associations between the changes in blood LDL- cholesterol, and the physical and biochemical characteristics of the participants as possible determinants of the variation in serum cholesterol response. This will include measurement of a common genetic polymorphism in APOLIPOPROTEIN E, as an established determinant of variation in blood cholesterol in response to dietary SFA.
3. To identify two subgroups of individuals whose blood LDL-cholesterol either responds ('Responders') or show little or no response ('Non-responders') on changing from Diet 1 to Diet 2, for participation in the follow-up study ('RISSCI-2'), which will be conducted at the Universities of Surrey, Reading and Imperial College London. In this follow-up study, the participants will be asked to repeat a similar study protocol as for RISSCI-1, and undergo more detailed measurements to determine how saturated fat is metabolised in the body.
Hypothesis:
In accordance with the variation in blood LDL-cholesterol response, that many studies have reported previously following substitution of dietary saturated with unsaturated fats, the investigators hypothesise that consuming Diet 1 (a high saturated fat diet) for 4 weeks followed by diet 2 (a low saturated fat/high unsaturated fat diet) for a further 4 weeks, will: 1) produce a variable distribution of responses in LDL-cholesterol that will enable the study of associations between the participants' baseline characteristics as possible determinants of the observed variation in blood LDL-cholesterol response, and 2) identify two distinct subgroups of individuals who either respond or show little or no response in their blood LDL- cholesterol. These distinct groups will be defined by the top and bottom \~10% of change in the concentration of blood LDL-cholesterol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High SFA diet to low SFA diet
Participants will undergo, sequentially, a high SFA diet (Diet 1) followed by a low SFA diet (Diet 2) for 4 weeks each. Study visits will occur before and after each dietary intervention period. To comply with current UK dietary recommendations, Diets 1 and 2 will both contain \~35% energy from total fat. These diets will be consumed within the homes of free-living participants, by the substitution of \~40g of habitual fat, with either SFA-rich or mono/poly-unsaturated fatty acid-rich (MUFA/PUFA) cooking oils, spreads and snack foods, while maintaining their habitual diet (consistent intake of protein and carbohydrates, including dietary fibre). This will be achieved using a dietary exchange model developed and peer-reviewed for a previous dietary intervention study ('DIVAS') at the University of Reading, U.K.
High SFA diet (Diet 1)
'Diet 1' will contain \~18% of its total energy as SFA .
Low SFA diet (Diet 2)
'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High SFA diet (Diet 1)
'Diet 1' will contain \~18% of its total energy as SFA .
Low SFA diet (Diet 2)
'Diet 2' will contain \~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting serum total cholesterol \< 7.5 mmol/l and triacylglycerol \< 2.3 mmol/l
Exclusion Criteria
* Medical history of myocardial ischemia or stroke in the past 12 months;
* Diabetes (defined as fasting glucose \> 7.0 mmol/l) or other endocrine disorders; kidney, liver, pancreas or gastrointestinal disorders
* Hypertension (blood pressure \> 140/90 mmHg),
* Cancer
* Medication for hyperlipidaemia (e.g. statins), hypertension, inflammation or prescribed antibiotics within the last three months
* Drinking in excess of 14 units of alcohol per week,
* Anaemia (\<130 g/L haemoglobin), or planning on a weight-reducing regime
* Taking any dietary supplements known to influence lipids/gut microbiota (eg. plant stanols, fish oil, phytochemicals, natural laxatives, probiotics and prebiotics)
* Any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention and metabolic study.
35 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Reading
OTHER
Imperial College London
OTHER
University of Surrey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruce A. Griffin
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce Griffin, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Surrey
Julie Lovegrove, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Reading
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Food and Nutritional Sciences, University of Reading
Reading, Berkshire, United Kingdom
Department of Nutritional Sciences, University of Surrey
Guildford, Surrey, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vafeiadou K, Weech M, Altowaijri H, Todd S, Yaqoob P, Jackson KG, Lovegrove JA. Replacement of saturated with unsaturated fats had no impact on vascular function but beneficial effects on lipid biomarkers, E-selectin, and blood pressure: results from the randomized, controlled Dietary Intervention and VAScular function (DIVAS) study. Am J Clin Nutr. 2015 Jul;102(1):40-8. doi: 10.3945/ajcn.114.097089. Epub 2015 May 27.
Koutsos A, Griffin BA, Antoni R, Ozen E, Sellem L, Wong G, Ayyad H, Fielding BA, Robertson MD, Swann J, Jackson KG, Lovegrove JA. Variation of LDL cholesterol in response to the replacement of saturated with unsaturated fatty acids: a nonrandomized, sequential dietary intervention; the Reading, Imperial, Surrey, Saturated fat Cholesterol Intervention ("RISSCI"-1) study. Am J Clin Nutr. 2024 Oct;120(4):854-863. doi: 10.1016/j.ajcnut.2024.07.032. Epub 2024 Aug 5.
Sellem L, Antoni R, Koutsos A, Ozen E, Wong G, Ayyad H, Weech M, Schulze MB, Wernitz A, Fielding BA, Robertson MD, Jackson KG, Griffin BA, Lovegrove JA. Impact of a food-based dietary fat exchange model for replacing dietary saturated with unsaturated fatty acids in healthy men on plasma phospholipids fatty acid profiles and dietary patterns. Eur J Nutr. 2022 Oct;61(7):3669-3684. doi: 10.1007/s00394-022-02910-2. Epub 2022 Jun 6.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RN0307A
Identifier Type: -
Identifier Source: org_study_id